Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 10/20 | 0.41 |
| ▸ | CFB | P00751 | 3/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20054403 | 0.94 | AAK1 (0.48) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL15116592 | 0.94 | AAK1 (0.48) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL15116752 | 0.90 | AAK1 (0.49) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL20054517 | 0.90 | AAK1 (0.49) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL15116854 | 0.86 | AAK1 (0.46) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL20054461 | 0.86 | AAK1 (0.46) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL16409177 | 0.85 | AAK1 (0.42) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL16391185 | 0.85 | AAK1 (0.48) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL20221198 | 0.83 | AAK1 (0.49) | AAK1SCN10ACFBGABRA1GABRG2 | |
| SCHEMBL15116808 | 0.83 | AAK1 (0.49) | AAK1SCN10ACFBGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885SCN10A 4191/4885CFB 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.